- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
7 Questions on Biomarkers for Management of Crohn Disease
When does management of Crohn disease warrant assessment of C-reactive protein and fecal calprotectin and when is endoscopy indicated? Test your IBD IQ.
New clinical practice guidelines from the American Gastroenterological Association (AGA) advise on use of biomarkers in the management of Crohn disease (CD).
Although managing CD has traditionally relied on endoscopy assessment of disease activity and mucosal healing, the AGA recognizes that reliance on endoscopy is limited by cost and resources as well as the test's invasiveness and patient acceptance. The guideline addresses these limitations by advising when biomarkers can serve as surrogates of endoscopic assessment.
The quiz above tests your familiarity with the role of the biomarkers C-reactive protein (CRP) and fecal calprotectin in the management of CD, as characterized in the AGA guideline. For a quick review, click here for the Patient Care Guideline Topline on the use of biomarkers in management of Crohn disease, based on the AGA recommendations.
Source: Ananthakrishnan AN, Adler J, Chachu KA, et al. AGA Clinical Practice Guideline on the role of biomarkers for the management of Crohn’s Disease. Gastroenterology 2023; 165:1367-1399. doi:10.1053/j.gastro.2023.09.029
FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment
October 14th 2025FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.
Clinical Tips for Using Antibiotics and Corticosteroids in IBD
January 5th 2013The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.
